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Abstract
Background: Transforming growth factor-βs (TGF-βs), bone morphogenetic proteins (BMPs) and
activins are important regulators of developmental cell growth and differentiation. Signaling by
these factors is mediated chiefly by the Smad family of latent transcription factors.
Results: There are a large number of uncharacterized cDNA clones that code for novel proteins
with homology to known signaling molecules. We have identified a novel molecule from the HUGE
database that is related to a previously known molecule, AMSH (associated molecule with the SH3
domain of STAM), an adapter shown to be involved in BMP signaling. Both of these molecules
contain a coiled-coil domain located within the amino-terminus region and a JAB (Domain in Jun
kinase activation domain binding protein and proteasomal subunits) domain at the carboxy-
terminus. We show that this novel molecule, which we have designated AMSH-2, is widely
expressed and its overexpression potentiates activation of TGF-β-dependent promoters.
Coimmunoprecipitation studies indicated that Smad7 and Smad2, but not Smad3 or 4, interact with
AMSH-2. We show that overexpression of AMSH-2 decreases the inhibitory effect of Smad7 on
TGF-β signaling. Finally, we demonstrate that knocking down AMSH-2 expression by RNA
interference decreases the activation of 3TP-lux reporter in response to TGF-β.
Conclusions: This report implicates AMSH and AMSH-2 as a novel family of molecules that
positively regulate the TGF-β signaling pathway. Our results suggest that this effect could be
partially explained by AMSH-2 mediated decrease of the action of Smad7 on TGF-β signaling
pathway.
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Background
TGF-β ligands belong to a large and expanding family of
multifunctional cytokines which include the activins,
inhibins, bone morphogenetic proteins (BMPs), growth/
differentiation factors, Mullerian inhibiting substance and
Nodal. Members of this family regulate a broad range of
physiological processes, including organogenesis, prolif-
eration, differentiation, adhesion, motility and apoptosis
[1,2]. Mutations in downstream components of the TGF-
β signaling pathways have been implicated in several
human diseases [3].
TGF-β superfamily members signal through a receptor
complex formed by the association of two transmem-
brane proteins designated I and II, each possessing serine/
threonine kinase activity (for reviews see [1,4,5]). TGF-β
binding induces the assembly of the type I and type II
receptors [6,7], thereby enabling the type II receptor to
phosphorylate and activate the type I receptor [8,9]. Acti-
vated type I receptors then phosphorylate Smad2 and
Smad3 receptor-regulated Smad proteins (R-Smads) at the
carboxy terminal motif SSxS [10,11]. Phosphorylated R-
Smads interact with Smad 4, the unique Co-Smad [11-
13]. This complex accumulates in the nucleus where it reg-
ulates transcriptional activity of several genes in associa-
tion with transcriptional activators and corepressors (for
reviews see [14-17]).
The specific transcriptional outcome in response to TGF-β
is achieved by the interplay of intracellular regulators at
different levels. Within the Smad family of proteins,
Smad6 and 7 (I-Smads) negatively regulate TGF-β signal-
ing [18-20]. Smad6 also inhibits BMP signaling, while
activin signaling is negatively regulated by Smad7 [21]. In
addition to the Smad proteins, other regulatory molecules
work as adapter and/or scaffolding proteins, such as
SARA, that mediates the access of Smads to activated
receptors [22]. Finally, the specific outcome of TGF-β sig-
naling is modulated by several other signaling pathways
(for review see [15,23]).
The human unidentified gene-encoded large proteins
database (HUGE) contains long cDNAs and is a valuable
tool to discover new proteins, and to predict structural fea-
tures with a possible functional relevance [24,25].
Through the analysis of the cDNA clones contained in this
database, we have identified a novel protein that is highly
similar to AMSH (associated molecule with the SH3
domain of STAM) [26]. Systematic analysis using specific
reporters for several pathways showed that this novel mol-
ecule, designated AMSH-2, positively regulates TGF-β sig-
naling system but not the TNF signaling pathway.
Results and discussion
Identification of a novel signaling molecule, AMSH-2
We have adopted a systematic strategy to identify and
characterize cDNAs encoding novel proteins containing
domains that have a role in signal transduction pathways
[27-29]. We have used the HUGE database as a primary
public resource as it contains mostly uncharacterized full-
length cDNAs. By analyzing the domain composition of
the predicted proteins, we identified a cDNA [Genbank
AB037794] with an open reading frame of 461 amino
acids (Figure 1A). The domain composition of the pre-
dicted protein was obtained by searching the SMART data-
base [30] and revealed a coiled-coil domain spanning
amino acids 149 to 176 in the N-terminus of the molecule
and a JAB domain [31-33] (amino acids 268 to 394)
located in the carboxy terminal region of the molecule
(Figure 1B). A search of GenBank database revealed a sim-
ilar molecule, AMSH, which had been identified on the
basis of its ability to interact with STAM and showed a
similar domain composition. Alignment of the novel pro-
tein against human AMSH revealed a 75% identity within
the JAB domain, with an overall identity of 56% between
the two molecules (Figure 1A). We have designated this
novel protein AMSH-2 after its paralog AMSH. Upon
searching the human genomic database, we found that
AMSH-2 gene was located on 10q23.33. A detailed analy-
sis of the genomic structure of the gene encoding for
AMSH-2 revealed that the coding region spans 10 exons
(Figure 1C). All the intron-exon boundaries followed the
GT/AG rule for splice junctions [34].
Expression of AMSH-2
In order to determine the tissue expression of AMSH-2, we
probed a Northern blot containing poly A+ mRNA from
several human tissues with a radiolabeled AMSH-2 probe.
We found a single band of approximately 2.3 kb which
was detected in almost all the tissues examined (Figure
2A, left panel). Probing a cancer cell line northern blot
revealed a band of similar size in most of the cell lines,
including HL60, Hela S3, Molt-4, Raji, SW480 and A549
(Figure 2A, right panel).
We corroborated the mRNA distribution of AMSH-2 by
performing a BLAST search against the EST database. We
found ESTs corresponding to AMSH-2 mRNA in brain,
testes, bone, pancreas, fetal liver, kidney, colon, stomach,
bone marrow, placenta, breast, pectoral muscle, hypotha-
lamus, ovary as well as in a number of cell lines of differ-
ent origins, including T cell leukemia, NT2 neuronal and
B-cell CLL [35]. These data indicate that, like AMSH [26],
AMSH-2 mRNA is widely expressed.
We raised an antibody against the carboxy terminus of
AMSH-2 and measured the expression of AMSH-2 protein
in different cell lines. For this purpose, HepG2 and 293TBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/2
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Sequence, domain architecture and genomic structure analysis of a novel protein AMSH-2 Figure 1
Sequence, domain architecture and genomic structure analysis of a novel protein AMSH-2. A) Alignment of 
AMSH family of proteins. Identical residues are shaded in yellow. B) The domain architecture of AMSH-2 was analyzed by 
SMART program. The coiled-coil region and the JAB domains are represented by green and red figures respectively. The num-
bers indicate the position of the domain within the protein sequence. C) Analysis of the genomic structure of the human gene 
encoding for AMSH-2. Only the coding exons are represented. Each exon is represented by a box with a length scaled to the 
size of the exon. The number of the amino acids encoded by each exon are indicated.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/2
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A) Northern blot analysis of AMSH-2 in different human tissues and cell lines Figure 2
A) Northern blot analysis of AMSH-2 in different human tissues and cell lines. Each lane contains 2 µg of poly A+ mRNA. The 
top panels show the result of hybridization of the membranes with a specific probe for AMSH-2 mRNA. The lower panels 
show β-actin reprobing of the membranes. The sizes of the transcripts are indicated in kb on the left. B) Expression of AMSH-
2 protein. Cell lysates from metabolically labeled 293T and HepG2 cells were immunoprecipitated with preimmune (PI) and 
AMSH-2 antiserum (I). A specific band for AMSH-2 can be observed in the lanes immunoprecipitated with AMSH-2 antiserum 
(indicated by an arrow). C) Expression of AMSH-2 Myc construct. 293T cells were transfected with the indicated constructs 
and metabolically labeled with S35. Cell lysates were immunoprecipitated with 9E10 monoclonal antibody and after SDS-poly-
acrylamide gel separation and blotting, the membrane was exposed. The arrow points a specific band corresponding to the 
Myc tagged AMSH-2 protein.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/2
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cells lines were metabolically labeled with 35S and cell
lysates were immunoprecipitated with preimmune or
anti-AMSH-2 antiserum. We observed a band with a
molecular weight of approximately 56 kDa, which is in
agreement with the predicted molecular weight of AMSH-
2. This band was specific for AMSH-2 as it was absent in
the samples immunoprecipitated with pre-immune
serum (Figure 2B).
AMSH-2 enhances gene expression of TGF-β-dependent 
promoters
In order to study the functional role of AMSH-2, we con-
structed several epitope-tagged versions of AMSH-2. The
entire open reading frame of AMSH-2 was subcloned by
PCR into pEF mammalian expression vectors that provide
a Myc or V5 epitopes at the C-terminus. Ectopic expres-
sion of AMSH-2/Myc was undertaken and confirmed by
metabolic labeling of 293T cells, followed by immuno-
precipitation with anti-Myc antibodies (Figure 2C).
We next examined the effect of overexpression of AMSH-
2 on a number of signaling pathways. Since AMSH-2 is
expressed in HepG2 and 293T cells, we chose these cell
lines for our assays. Given the similarity between AMSH-
2 and AMSH, and the ability to AMSH to regulate BMP sig-
naling, we hypothesized that AMSH-2 may affect signal-
ing by TGF-β. We first tested the effect of AMSH-2
overexpression on TGF-β signaling pathway using p3TP-
lux reporter plasmid which is a standard reporter to eval-
uate TGF-β signaling [6]. This reporter construct contains
the luciferase gene under the control three consecutive
TPA response elements and a 96 bp fragment of the PAI-1
promoter that is regulated by TGF-β and is also highly
inducible in response to TGF-β. Overexpression of AMSH-
2 in HepG2 cells increased the level of luciferase activity
driven by the 3TP promoter upon TGF-β stimulation as
compared to cells transfected with vector alone (Figure
3A). As this promoter is derived from the Plasminogen
activator inhibitor-1 (PAI-1) promoter, we also tested the
effect on PAI-1 luciferase activity [36]. When we cotrans-
fected AMSH-2 into HepG2 cells together with this
reporter, a similar increase in the luciferase levels was
observed indicating that AMSH-2 is likely a positive regu-
lator of TGF-β signaling (Figure 3B).
To account for possible non-specific effects, we tested the
effect of AMSH-2 overexpression on the TNF signaling
pathway. We used an ELAM-luciferase reporter construct
as a reporter for activation of this pathway. This reporter
contains the ELAM-1 promoter (-730 to +52) and is well
known to be induced by TNF stimulation [37]. We there-
fore cotransfected 293 cells with ELAM-luciferase and
either AMSH-2, empty vector or TRAF2, a prototypical
member of the TRAF family of adapter proteins known to
potentiate TNF signaling pathway [38-40]. We did not
observe any increase in the luciferase levels in AMSH-2
transfected cells as compared with the empty vector,
although overexpression of TRAF2 led to a significant
upregulation of the promoter (Figure 3C). Taken together,
these results imply that the AMSH-2 regulates TGF-β sign-
aling pathway.
AMSH-2 negates the inhibitory effect of Smad7 on TGF-β 
signaling
The ability of AMSH-2 to regulate TGF-β signaling could
be explained by several mechanisms, including interac-
tion with Smad2, Smad3, Smad4, or Smad7 [41]. To
determine whether AMSH-2 interacts with these Smads,
we coexpressed AMSH-2 with epitope tagged Smad con-
structs in 293T cells. As shown in Figure 4A, we observed
an association between AMSH-2 and Smad7 but not with
Smads 3 or 4 (Figure 4A). We also observed association
between Smad2 and AMSH-2. These findings are similar
to that observed for AMSH, since this molecule interacts
strongly with Smad6 and 7; but differ in that AMSH does
not with any R-Smads [41].
Because AMSH-2 interacts with Smad7, we also analyzed
the effect of AMSH-2 on the ability of Smad7 to inhibit
TGF-β signaling in HepG2 cells. As expected, overexpres-
sion of Smad7 attenuated the induction of p3TP-luci-
ferase activity by TGF-β (Figure 4B). Interestingly,
overexpression of AMSH-2 negated the inhibitory effect of
Smad7 on p3TP expression stimulated by TGF-β (Figure
4B). Therefore AMSH-2 can rescue the inhibitory effects of
Smad7 on TGF-β signaling pathway. Given the sequence
similarity between AMSH and AMSH-2, it is indeed possi-
ble that AMSH-2 also interacts with Smad6. Smad6 has
been shown to inhibit the TGF-β pathway [42] and AMSH
is able to rescue the inhibitory effect of Smad6 on BMP
signaling pathway [41]. If AMSH-2 is able to interact with
Smad6, the effect of AMSH-2 on TGF-β signaling pathway
could be explained by its interaction with both Smad7
and Smad6.
AMSH-2 is a positive regulator of TGF-β-dependent 
transcriptional activation
The use of small interfering RNAs (siRNA) has been
proven a powerful tool to suppress the expression of spe-
cific proteins in mammalian cells [43,44]. We have shown
that overexpression of AMSH-2 positively regulates TGF-
β-dependent transcriptional activation of 3TP-lux
reporter. To assess the effect of depletion of endogenous
AMSH-2, we designed a specific siRNA to silence AMSH-
2. This siRNA was cotransfected in HepG2 cells and the
effect on the transcriptional activity of the 3TP driven luci-
ferase reporter was analyzed. As a positive control we used
an siRNA targeted against Smad7. Cotransfection of
siRNA specific for AMSH-2 cause a decrease in the luci-
ferase activity upon stimulation with TGF-β whenBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/2
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A) Effect of AMSH-2 on TGF-β induced transcriptional activity of 3TP driven luciferase Figure 3
A) Effect of AMSH-2 on TGF-β induced transcriptional activity of 3TP driven luciferase. HepG2 cells were cotransfected with 
3TP-lux reporter together with the empty vector or increasing amounts of AMSH-2 Myc construct. Twenty-four hours post-
transfection, cells were serum-starved and left untreated (white bars) or stimulated (black bars) with 5 ng/ml TGF-β1 for 16–
20 h before the luciferase and β-galactosidase activities were measured. B) Effect of AMSH-2 on TGF-β induced transcriptional 
activity of PAI-1 luciferase. HepG2 cells were cotransfected with PAI-1 reporter together with the empty vector or 0.9 µg/ml 
of AMSH-2 Myc construct. A similar procedure as described in A was followed. C) AMSH-2 does not stimulate NF-kB signaling 
pathway. 293 cells were cotransfected with ELAM luciferase reporter construct together with an empty vector, 0.9 µg/ml of 
AMSH-2 Myc construct or 0.9 µg/ml of TRAF-2, used as a positive control. Forty-eight hours posttransfection, luciferase and 
β-galactosidase activities were measured.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/2
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A) AMSH-2 interacts with Smad2 and Smad7, but not with Smad3 or Smad4 Figure 4
A) AMSH-2 interacts with Smad2 and Smad7, but not with Smad3 or Smad4. Vector or AMSH-2 V5 construct were coex-
pressed in 293T cells together with the Smad proteins as indicated on the top of the figure. Lysates were immunoprecipitated 
with anti-V5 antibody and western blotted with anti-Flag or anti-HA antibodies. To control for Smad and AMSH-2 protein 
expression part of the lysates were immunoprecipitated with anti-Flag, anti-HA or anti-V5 antibodies and western blotted with 
the same antibodies. B) Smad7 inhibitory effect on TGF-β signaling pathway is rescued by AMSH-2. HepG2 cells were cotrans-
fected with 3TP-lux reporter together with the empty vector or 10 ng/ml of Smad7 with or without 0.3 µg/ml of AMSH-2 Myc 
construct. Twenty-four hours posttransfection, cells were serum-starved and left untreated (white bars) or stimulated (black 
bars) with 5 ng/ml TGF-β1 for 16–20 h before luciferase and β-galactosidase activities were measured.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/2
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compared with cells cotransfected with a commercially
available randomly ordered RNA scrambled RNA. As
expected, we observed an increase in luciferase activity in
the cells transfected with a siRNA specific for Smad7 (Fig-
ure 5). These knock down experiments confirm that
AMSH-2 positively regulates TGF-β signaling pathway.
Conclusions
Our results indicate that AMSH-2 is a positive regulator of
TGF-β signaling. This effect might be mediated through
the interaction with the inhibitory Smad7 as AMSH-2 is
capable of negating the inhibitory effects of Smad7 in
TGF-β signaling pathway. Further, use of siRNA to knock
down the expression of AMSH-2 reduces signaling by
TGF-β. Similar to our studies, it has been suggested that
AMSH might be involved in TGF-β signaling. AMSH can
interact with both I-Smads (i. e. Smads 6 and 7) and is a
positive regulator of BMP signaling pathway [41]. The
high degree of homology between these paralogs suggests
that AMSH-2 might also interact with Smad6, and there-
fore might regulate BMP signaling. Although further
research needs to be conducted to elucidate the exact
mechanism of action of AMSH-2, it is clear that AMSH
and AMSH-2 belong to a new family of molecules that
positively regulate TGF-β signaling pathway.
Methods
cDNAs and constructs
A human cDNA clone [Genbank AB037794] was used as
described [24,25]. To generate wild type AMSH-2 expres-
sion vector with a carboxy-terminal Myc epitope, we sub-
cloned AMSH-2 open reading frame into the Nco I and
Xho I sites of pEF/myc/cyto (Invitrogen, Carsbad, CA) by
standard PCR procedures using the primers: AAAACCAT-
GGATCAGCCTTTTACTGTGAATTC (5' primer) and
AAACTCGAGCTGTTCAGATGGTGATGATGAC (3'
primer). To generate AMSH-2 V5 carboxy-terminal-tagged
expression vector, the open reading frame of AMSH-2 was
subcloned into Nco I and Xho I sites of pEntr4 (Invitro-
gen) using the same 5' primer as described above and
AAACTCGAGAGCTGTTCAGATGGTGATGATGACCTAG
(3' primer), and transferred to pEF1/V5-HisB (Invitro-
gen), which has been previously made gateway compati-
ble by inserting a cassette in the EcoRV site.
3TP-lux, PAI-1-luc, pELAMP-luc+, TRAF2, Flag-tagged
Smad7, Smad3, have been previously described [6,20,36-
38,45] while Flag-tagged Smad2 and HA-tagged Smad4
were generously provided by Joan Massague.
Northern blot analysis
Human tissue northern blot II and cancer cell line blot
were obtained from CLONTECH (Palo Alto, CA). We iso-
lated and radiolabeled an AMSH-2 cDNA (nucleotides
1088–2010) produced by digestion of AMSH-2 cDNA
clone with HindIII and SphI. Hybridization signals were
detected on a BAS-2000 bioimaging analyzer (Fuji film,
Tokyo, Japan). After exposure, the blots were stripped and
reprobed with beta-actin to control for equal amounts of
PolyA+ RNA loading.
Cell culture and antibodies
293 and 293T cells were grown in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine and penicillin/streptomycin.
HepG2 cells were grown in MEM supplemented with 10%
fetal bovine serum, non essential amino-acids, sodium
pyruvate and penicillin/streptomycin.
The peptide corresponding to the C-terminus of human
AMSH-2 was synthesized by Boston Biomolecules, Inc
(Woburn, MA). The specific AMSH-2 rabbit polyclonal
antibody (anti-AMSH-2) was raised at Covance Research
Products Inc. (Denver, PA). The following antibodies were
obtained: (i) c-Myc mAb 9E10 (Covance Research
AMSH-2 RNA interference has a negative effect on TGF-β  signaling pathway Figure 5
AMSH-2 RNA interference has a negative effect on 
TGF-β signaling pathway. HepG2 cells were transfected 
with 3TP-lux reporter and scramble, laminA/C, AMSH-2 or 
Smad7 siRNA duplexes as indicated in the bottom of the 
graph. Forty-eight hours posttransfection cells were serum-
starved and left treated (black bars) or not (white bars) with 
5 ng/ml TGF-β1.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/2
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Products Inc);(ii) anti-V5 and anti-V5 HRP antibodies
(Invitrogen); (iii) anti-Flag HRP (UPSTATE, Lake Placid,
NY);and (v) anti-HA 12CA5, anti-HA HRP (Roche Diag-
nostics Corp, Indianapolis, IN).
Metabolic labeling and immunoprecipitation
To test endogenous expression of AMSH-2, 293T and
HepG2 cells were metabolically labeled with 35S
methionine and 35S cysteine and lysed in modified RIPA
buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 1 mM EDTA,
1% NP-40, 0.25% sodium deoxycholate) with 1 mM
sodium orthovanadate and protease inhibitors. Samples
were incubated either with pre-immune serum or AMSH-
2 antiserum. Immunoprecipitated proteins were resolved
by SDS-PAGE. To test expression of the Myc-tagged
AMSH-2 construct, cells were transfected with 15 µg of
DNA using the standard calcium phosphate method.
Twenty-four h postransfection, the cells were metaboli-
cally labeled for 16 h. and subsequently lysed and immu-
noprecipitated with anti-Myc antibody as above.
Luciferase assays
HepG2 cells were transfected with 0.5 µg of the corre-
sponding luciferase reporter, 50 ng of β-galactosidase
reporter and 4.5 µg of DNA. Twenty-four h postransfec-
tion, the cells were depleted from serum and stimulated
for 16–20 h with 5 ng/ml of purified recombinant human
TGF-β1 (R&Dsystems. Inc. Minneapolis, MN). Luciferase
and β-galatosidase activities were measured according to
manufacturer's instructions (Tropix, Bedford, MA). Meas-
urements were corrected by β-galactosidase activity. The
experiments were repeated at least three times.
Coimmunoprecipitation experiments
293T cells were cotransfected with 13 µg of AMSH-2 V5
construct and 2 µg of the corresponding Smad constructs.
After 48 h, the cells were lysed in lysis buffer (150 mM
NaCl, 50 mM Tris, pH 7.5, 1 mM EDTA, 1% NP-40) with
1 mM sodium orthovanadate and protease inhibitors.
Lysates were incubated with anti-V5 antibody, and the
resulting immunocomplexes were separated in SDS-
PAGE. Blots were probed with the indicated HRP conju-
gated antibody.
siRNA experiments
To target AMSH-2 and Smad 7, we designed 21 nt siRNA
duplexes: AACAATTCCTTGCTGAATGTA and AACCG-
CAGCAGTTACCCCATC, according to [44]. All siRNA
duplexes including lamin A/C siRNA duplexes and scram-
bled siRNA were obtained from Dharmacon Research.
Inc. (Lafayette, Colorado).
HepG2 cells grown in 6 well plates were transfected with
250 ng of 3TP-lux reporter, 50 ng of β-galactosidase
reporter and 0.12 nmol of the corresponding siRNA
duplex. After 48 h of transfection cells were depleted from
serum and treated with 5 ng/ml TGF-β1. Luciferase and β-
galactosidase activities were measured after 17 h
stimulation.
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